Evidence map›Paper›PMID 39628470›Full record

ArticleBiomaterials research2024

Res@LDH: A Novel Nanohybrid Therapeutic for Ischemia-Reperfusion Injury with Dual Reactive Oxygen Species Scavenging Efficiency.

Min Liu, Siyuan Liu, Yafan Bai, Mingru Zhang, Duo Zhang, Ruijin Sun, Guyan Wang, Yulong Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Advanced Therapeutic Approach Based on LDHs-Mimetic Oxidoreductase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Min LiuDepartment of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Siyuan LiuDepartment of Anesthesiology, Affiliated Hospital of Nantong University, Nantong 226001, China.
Yafan BaiDepartment of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Mingru ZhangDepartment of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Duo ZhangSchool of Science, China University of Geosciences, Beijing (CUGB), Beijing 100083, China.
Ruijin SunSchool of Science, China University of Geosciences, Beijing (CUGB), Beijing 100083, China.
Guyan WangDepartment of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Yulong MaDepartment of Anesthesiology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic stroke poses a global health challenge, necessitating effective therapeutic interventions given the limited time window for thrombolytic therapy. Here, we present Res@LDH, a novel nanohybrid therapeutic agent boasting a dual reactive oxygen species scavenging efficiency of approximately 90%. Comprising Ge-containing layered double hydroxide nanosheets (Ge-LDH) as a drug nanocarrier and resveratrol as a neuroprotective agent, Res@LDH demonstrates enhanced permeability across the blood-brain barrier, ensuring high biocompatibility and stability. We explored the potential of Res@LDH in mitigating oxidative stress injury induced by middle cerebral artery occlusion and reperfusion in mice, as well as H

Identifiers

PMID39628470
PMCPMC11612122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.